
PaySign Inc (PAYS) Stock Forecast & Price Target
PaySign Inc (PAYS) Analyst Ratings
Bulls say
PaySign is supported by rapid momentum in its Pharmaceutical Patient Affordability business, where 2Q revenue jumped 89% Y/Y to $14.6M and active programs rose to 148, with 17 net new campaigns added in the first half of 2026 and another 9 in July. Its profitability is also inflecting sharply as mix shifts toward higher-margin Pharma offerings, driving 2Q adjusted EBITDA up 113% Y/Y to $9.6M and margin expansion to 34.0%, while management raised 2026 guidance to 39%-43% revenue growth and $35.0M-$38.0M adjusted EBITDA. A strong balance sheet, including $27.4M of unrestricted cash, $149.1M of restricted cash, no debt, and $6.8M of 2Q adjusted free cash flow, gives it flexibility for acquisitions and repurchases while the Plasma segment and Apherion add further growth optionality.
Bears say
PaySign is a highly niche-dependent payments provider whose fundamentals remain vulnerable because the domestic Plasma Donor Compensation business generated just over 55% of revenue in 2025, while center counts fell sequentially and to 561 in 2Q26 after a customer closed locations. Although revenue in that segment grew 21% Y/Y to $13.0M in 2Q26, the company has already shown how quickly demand shocks can pressure results, as 2020 revenue dropped 30% Y/Y to $24M and adjusted EBITDA swung to a $2.8M loss from $10.1M in 2019. Its outlook is further restrained by intense competition, regulatory and bank-partner dependence, and the loss of legacy Pharma Prepaid contracts in late 2022, which weakens diversification and lowers the quality of recurring revenue.
This aggregate rating is based on analysts' research of PaySign Inc and is not a guaranteed prediction by Public.com or investment advice.
PaySign Inc (PAYS) Analyst Forecast & Price Prediction
Start investing in PaySign Inc (PAYS)
Order type
Buy in
Order amount
Est. shares
0 shares